Follow-On Biologics: White House Calls 7 Years Of Exclusivity A "Generous Compromise"
This article was originally published in The Pink Sheet Daily
Executive Summary
Reply to Rep. Waxman notes that "a serious review of FDA's existing authorities is underway."
You may also be interested in...
FOBs Help Wanted: Waxman Appeals To Obama
FDA should start approving follow-on biologics even in the absence of legislation, House committee chairman tells president in bid to increase his negotiating leverage.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.